eSpCas9 mRNA(Cap1, m1Ψ)
¥1000 | |
RP-A00018 | |
|
|
|
|
|
¥1000 | |
RP-A00018 | |
|
|
|
|
|
The eSpCas9 mRNA expresses enhanced-specificity SpCas9 protein, with sequence originally from Slaymaker et al., Science (2015 Dec 1). eSpCas9 significantly reduces off-target effects (by more than 10-fold), while maintaining high on-target genome editing efficiency.
|
Form | Liquid |
Concentration | 1mg/mL |
Full mRNA length | 4479nt |
Full mRNA Molecular Weight | 1457890 |
Storage buffer | 1mM Sodium citrate, pH6.5 |
Storage condition | Store at -20°C for short term (<3 months), store at -80°C for long term. |
Appearance | Clear and free of foreign particles |
RNA Length | Expected size band detected |
RNA Content | Target ± 5% |
Integrity | ≥ 75% |
OD260/OD280 | 1.70 ~ 2.30 |
Capping Efficiency | ≥ 90% |
Endotoxin | < 10 EU/mg |
pH | Target ± 0.5 |
Transfect a total of 0.5-1.5 µg of eSpCas9 mRNA and sgRNA per well (recommended molar ratio 1:10), using a transfection reagent, electroporation, or LNP encapsulation in a 24-well plate (~2 × 10⁵ cells/well). Assess genome editing efficiency 48-72 hours post-transfection via sequencing and ICE analysis. |
eSpCas9 mRNA and TRAC sgRNA (molar ratio 1:10) were transfected into 2×105 HEK293T cells using LNP. 48h after transfection, cells were collected to extract gDNA. Genome editing efficiency were verified by PCR, Sanger sequencing and ICE analysis. »
Expression of eSpCas9 mRNA in A549 cells. The eSpCas9 expression was measured 48 hours after transfection by ELISA. »
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.